CClinicalTrials.gg
RecruitingNCT06883357Updated May 18, 2026

The Effects of Home-based Graded Repetitive Arm Supplementary Program Group on Stroke.

An interventional study of Graded repetitive arm supplementary program (GRASP) in Stroke, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

Graded repetitive arm supplementary program (GRASP) is a self administrated, home-based rehabilitation program and has been incorporated in Canadian Stroke Best Practice Recommendations. Past studies indicated that the home-based GRASP program could facilitate the motor function and motor recovery and prevent learned nonuse of affected upper limb of stroke patients. There is lacking of research and application of the home-based GRASP program in Taiwan. Therefore, this study aims to explore the effects of the home-based GRASP program, which is mainly executed in the form of group intervention, on the affected upper limb of stroke patients.

02

Conditions studied

  • Stroke

Browse trials for

03

In context

Stroke

7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.

This study's planned enrollment of 52 is close to the median of 50 across 5,369 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,563 studies on the registry; 569 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age is above 20 years old.
  2. Onset of first stroke complicated with hemiplegia or hemiparesis.
  3. The affected upper limb remains partially voluntary movements including lifting to chest level and holding for five seconds; slight flexion and extension of wrist and hand.
  4. Understanding and complying with two-steps commands.
  5. Understanding the content of trial and willing to sign informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Complicating with other neurological disease.
  2. Having Orthopedic diseases affecting the movements of upper limbs.
  3. Having symptoms of pain to affect the movements of upper limbs.
  4. Unstable vital sign or medical condition.
  5. Participating another rehabilitative or drug research meanwhile.
  6. Receiving botulinum toxin injection within three months.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    GRASP group

    Behavioral: Graded repetitive arm supplementary program (GRASP)

  • No intervention
    Control group

Interventions

  • BehavioralGraded repetitive arm supplementary program (GRASP)

    Graded repetitive arm supplementary program (GRASP) is a self administrated, home-based rehabilitation program. home-based GRASP program could facilitate the motor function and motor recovery and prevent learned nonuse of affected upper limb of stroke patients. Participants in experimental group will receive Home GRASP program which will be executed 1hour at home per day. In addition, Participants will be requested to return hospital for follow-up and adjusting the training program in group discussion 3 times per week, lasting 4-6 weeks, and totally 12-18 sessions.

06

What researchers measure

Primary outcomes

  1. Fugl-Meyer Assessment for upper extremity (FMA-UE)

    The Fugl-Meyer Assessment for upper extremity (FMA-UE) includes 33 items for the motor recovery of upper limb. Each item is a 3 point ordinal scale. The total score ranges from 0 to 66, higher score means better motor recovery.

    Time frame: From enrollment to the end of treatment at 6 weeks

  2. Jamar Hydraulic Hand Dynamometer (Jamar Dynamometer)

    The Jamar Hydraulic Hand Dynamometer (Jamar Dynamometer) is a tool used for assessing the strength of grip, lateral pinch, and palmar pinch. The muscle strength is recorded in kilograms or pounds.

    Time frame: From enrollment to the end of treatment at 6 weeks

  3. Action Research Arm Test (ARAT)

    The Action Research Arm Test (ARAT) is developed for measuring the motor function of affected upper limb after stroke. ARAT includes subscales of grasp, grip, pinch, and gross movement. The total score ranges from 0 to 57, higher score means better motor function.

    Time frame: From enrollment to the end of treatment at 6 weeks

Secondary outcomes

  1. Chedoke Arm and Hand Activity Inventory (CAHAI)

    The Chedoke Arm and Hand Activity Inventory (CAHAI) is developed for measuring the level of function and involvement of the affected upper limb in bimanual tasks. It contains 13 tasks and the total score is ranged from 13 to 91. The higher score means better motor function and involvement.

    Time frame: From enrollment to the end of treatment at 6 weeks

  2. Rating of Everyday Arm-use in the Community and Home Scale (REACH-Scale)

    The Rating of Everyday Arm-use in the Community and Home Scale (REACH-Scale) is a self-evaluation scale designed for stroke patients to measure the involvement of the affected upper extremity in everyday life. The score ranged from 0 to 5 and higher score indicate the more utilization of affected upper extremity.

    Time frame: From enrollment to the end of treatment at 6 weeks

  3. Stroke Impact Scale Version 3.0 (SIS 3.0)

    The Stroke Impact Scale Version 3.0 (SIS 3.0) is a self-evaluated assessment for measuring the quality of life of patients with stroke. In our study, the strength domain(total score:4-20) and hand function domain(total score:5-25), and the an extra question on stroke recovery(total score:0-100)was used. The higher score means better quality of life.

    Time frame: From enrollment to the end of treatment at 6 weeks

07

Study locations

1 of 1 sites recruiting
  • National Taiwan University Hospital Hsin-Chu Branch
    Hsinchu, 300, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06883357
Lead sponsor
National Taiwan University Hospital
Responsible party
Sponsor
First posted
Mar 19, 2025
Start date
Mar 17, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 18, 2026

Study contacts

Chia-Yi Lin
Contact
G04812@hch.gov.tw
+886-3-5326151#523509
Chia-Yi Lin
study director · Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital Hsin-Chu Branch

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion